Amyris, Inc.

193 articles about Amyris, Inc.

• Amyris Announces Operational and Financial Restructuring to Advance Strategic Transformation

  8/10/2023

  Amyris, Inc. announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

• Amyris Announces CEO Transition and Global Reduction in Force

  6/26/2023

  Amyris, Inc. announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately.

• Amyris Initiates Strategic Transformation Program and Secures Funding

  6/5/2023

  Amyris, Inc. announced that its Board of Directors has engaged the Business Recovery Services unit of PricewaterhouseCoopers and established a subcommittee of the Board, made up of three independent directors, working with Management, to execute on a transformation program to accelerate improvements to the Company's cost and capital structure and liquidity.

• AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE

  5/19/2023

  Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.

• Amyris, Inc. Reports First Quarter 2023 Financial Results

  5/9/2023

  Amyris, Inc. announced financial results for the first quarter ended March 31, 2023.

• AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

  5/2/2023

  Amyris, Inc. today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets

• Amyris Reports Q1 2023 Revenue

  4/24/2023

  Amyris, Inc., a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, provided an update on first quarter revenue.

• Amyris Closes Strategic Transaction With Givaudan

  4/5/2023

  Amyris, Inc. announced that it has completed the previously announced strategic transaction with Givaudan SA for the worldwide exclusive licensing of certain cosmetic ingredients, including Neossance® Squalane, the highest performant emollient, Neossance® Hemisqualane, the plant-based silicone alternative, and CleanScreen™, the sustainable sun protector.

• AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

  3/15/2023

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the fourth quarter and full year ended December 31, 2022.

• AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

  2/28/2023

  Amyris, Inc. today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets.

• Amyris to Present at the 41st Annual J.P. Morgan Health Care Conference

  1/4/2023

  Amyris, Inc., a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform announced that management will present at the 41st Annual J.P. Morgan Health Care Conference on Wednesday, January 11, 2023, at 11:15 am PT in San Francisco.

• Amyris Announces $50 Million Registered Direct Offering and Concurrent Private Placement

  12/29/2022

  Amyris, Inc. announced that it has entered into a definitive purchase agreement for the purchase and sale of 20,000,000 shares of the Company's common stock and warrants to purchase up to an aggregate of 15,000,000 shares of common stock in a registered direct offering.

• Amyris Successfully Advances Strategic Transaction

  12/27/2022

  Amyris, Inc. announced that it has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris' ingredients.

• Amyris, Inc. Reports Third Quarter 2022 Financial Results

  11/8/2022

  Amyris, Inc., a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, announced financial results for the third quarter ended September 30, 2022.

• AMYRIS TO HOST THIRD QUARTER 2022 FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 8

  11/1/2022

  Amyris, Inc. today announced that it will issue its financial results for the third quarter ended September 30, 2022, on the afternoon of Tuesday, November 8, 2022, after closing of the financial markets.

• Amyris to Participate at September 2022 Investor Conferences

  9/7/2022

  Amyris, Inc. announced that management will participate in fireside chats moderated by equity research analysts, and provide updates, at two upcoming investor conferences.

• AMYRIS, INC. REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

  8/9/2022

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the second quarter ended June 30, 2022.

• AMYRIS TO PARTICIPATE AT THE UBS GENOMICS 2.0 AND MEDTECH INNOVATIONS SUMMIT

  8/3/2022

  Amyris, Inc. (Nasdaq: AMRS), today announced that management will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 10, 2022, at 3:00 pm PT/ 6:00 pm ET in Dana Point, CA.

• Amyris Barra Bonita Fermentation Plant Begins Industrial Production

  6/23/2022

  Amyris, Inc. announced that it has successfully started fermentation at its new precision fermentation plant in Barra Bonita, Brazil.

• AMYRIS TO PARTICIPATE AT THE OPPENHEIMER 22nd ANNUAL CONSUMER CONFERENCE

  6/7/2022

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that management will participate in a virtual fireside chat at the Oppenheimer 22nd Annual Consumer Conference on Tuesday, June 14, 2022.